

Celgene Corporation **Investor Relations Department** 86 Morris Avenue Summit, NJ 07901 **United States**

Visit IR website □ Sign-up for e-mail alerts

NASDAQ: CELG	
Last Trade:	135.63
Trade Time:	10:35 AM ET Jul 20, 2017
Change:	0.63 1 (0.467%)
Day Range	134.60 - 136.26
52-Week Range	96.93 - 136.12
Volume	687,289

Stock information is provided by eSignal. stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery. development and commercialization of innovative therapies for the treatment of cancer and immuneinflammatory related diseases. Our portfolio of commercial products include REVLIMID®. VIDAZA[®], THALOMID[®], POMALYST®/IMNOVID®. ABRAXANE®. OTEZLA® and ISTODAX[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs... (more)

Stock Performance



Press Releases [View all]

Jul 5, 2017

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor **Program for Solid Tumor Cancers**

Jul 5, 2017

Celgene Corporation to Announce Second Quarter 2017 Results on July 27, 2017

Jun 22, 2017

Celebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgene's SHOW MORE OF YOU Campaign

Jun 19, 2017

Celgene Announces Clinical Data Evaluating Broad Range of Blood Cancers to Be Presented at EHA 2017

Jun 17, 2017

Updated Data from Phase IIIb MAGNIFY Study of REVLIMID (lenalidomide) and Rituximab Combination (R2) Show Clinical Activity and Responses in Relapsed/Refractory Follicular and Marginal Zone Lymphoma

Upcoming Events [View all]

Jul 27, 2017 9:00 AM ET Celgene Corporation Q2 2017 Celgene Corp. Earnings Conference Call

Events [View all]

Financials [View all]

Feb 10, 2017 Annual Report (10-K)

Apr 27, 2017 Proxy Statement (DEF 14A)

Apr 27, 2017 Quarterly Report (10-Q)

Oct 27, 2016 Quarterly Report (10-Q)

Jul 28, 2016

Quarterly Report (10-Q)